Squamous Cell Carcinoma

Viome Life Sciences highlights clinical results

The study was published December 8 in NPJ Genomic Medicine and describes a diagnostic method based on a saliva sample for detecting early-stage oral squamous cell carcinoma. The test received breakthrough device designation in May 2021 from the U.S. Food and Drug Administration (FDA). Lab technology for the test was developed at Los Alamos National Laboratory.

December 19, 2021

Sysmex Inostics touts liquid biopsy findings at ASCO

The featured data will show how the company's SafeSEQ cfHPV-DNA Test (HPV-SEQ) detects cell-free HPV DNA, enabling monitoring for patients with HPV and oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer.

June 3, 2021

Viome's screening tool given 'breakthrough device' designation

Viome's technology and AI platform is designed to screen for oral cancer and throat cancer, which are traditionally diagnosed manually by a primary care clinician by visual or tactile senses in a subjective way, often going undiscovered.

May 6, 2021

Universal Diagnostics touts blood-based lung cancer test

Presented at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference, the test uses methylation status measurement of the tumor-derived portion from cell-free DNA (cfDNA) in plasma for patient classification. Researchers examined plasma samples of 37 lung cancer patients and 71 asymptomatic age, gender, and smoking-history matching controls.

January 28, 2021

Researchers get $3.3M to study AI in oral cancer

The U.S. National Cancer Institute awarded the five-year grant to a group led by Anant Madabhushi, PhD, the Donnell Institute Professor of Biomedical Engineering at CWRU and head of the Center for Computational Imaging and Personalized Diagnostics, and Dr. James Lewis Jr., a pathology, microbiology, and immunology professor at Vanderbilt University Medical Center.

January 5, 2021

Google reports pathology AI helps predict survival in cancer patients

The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.

June 17, 2020

Most Popular

Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing

Simple blood test can detect PTSD biomarkers

Rapid nirmatrelvir treatment in study reduced long-COVID risk

Illumina NGS software to enable tertiary analysis for oncology, rare disease

AmoyDx PLC Panel gets Japanese approval as companion diagnostic for NSCLC

Serum protein in study predicted which patients might die without a liver transplant

FDA approves Agilent assay for lung cancer

The test, called PD-L1 IHC 28-8 pharmDx, will help physicians identify patients with metastatic NSCLC who qualify for treatment with a dual immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both of which are manufactured by Bristol Myers Squibb.

May 17, 2020

Agilent's PD-L1 test gets OK for head, neck cancer in Europe

The assay is approved for use as a companion diagnostic with the checkpoint inhibitor pembrolizumab (Keytruda, Merck), the company said in a statement. Keytruda is approved as a monotherapy or in combination with chemotherapy for the first-line treatment of metastatic or unresectable recurrent HNSCC in adults whose tumors express PD-L1 with a combined positive score of at least 1.

November 21, 2019

Blood work tracks immunotherapy in GI cancers

Hyperprogressive disease -- or rapid tumor expansion -- is an effect of immune checkpoint blockade drug therapy that has been getting more attention in recent years with the rising use of PD-1 inhibitors across tumor types. It is distinct from pseudoprogression, where there is tumor growth initially with immunotherapy treatment, but it is followed by a response.

July 25, 2019

Journal eyes liquid biopsy's promise with special edition

Liquid biopsy detects markers for disease in bodily fluids less invasively than tissue biopsy. This makes it easier for physicians to monitor cancer progression in patients and to adjust treatment regimens as cancer cells develop resistance to existing therapies.

April 21, 2019

Page 1 of 1